PTC/SB/96 (01-08)
Approved for use through 04/30/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: Boris Leschinsky		
Application No./Patent No.: 6,827,730 Filed/Issue Date: 12/07/2004		
Entitled: REDUCED DIAMETER STENT/GRAFT DEPLOYMENT CATHETER		
Endovascular Technologies, Inc. , 8 <u>Corporation</u> (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)		
states that it is:  1.  the assignee of the entire right, title, and interest; or		
an assignee of less than the entire right, title and interest     (The extent (by percentage) of its ownership interest is%)		
in the patent application/patent identified above by virtue of either:		
A A assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 010853 Frame 0516 or for which a copy thereof is attached.  OR		
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:		
1. From:		
2. From:		
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.		
From:     To:     The document was recorded in the United States Patent and Trademark Office at		
Reel Frame, or for which a copy thereof is attached.		
Additional documents in the chain of title are listed on a supplemental sheet.		
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.		
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]		
The undersigned (whose title is supplied below) is puthorized to act on behalf of the assignee.		
Tune 9, 2009		
Signature Date		
Victoria A, Polssant (861) 949-4553  Printed or Typed Name Telephone Number		
Patent Agent		
Title		

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gamering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## LIMITED AUTHORIZATION TO ACT ON BEHALF OF ASSIGNEE REGARDING CERTAIN PATENT MATTERS EFFECTIVE THROUGH: December 31, 2009

I, Lawrence J. Knopf, as Senior Vice President and Deputy General Counsel of Boston Scientific Corporation, the controlling corporation of:

A-Med Systems, Inc.; Advanced Stent Technologies, Inc.; AFx, Inc.; AMS Medinvent S.A.; BEI Medical Systems; BEI Medical Systems Operating Company (formerly known as Xylog Corporation); BEI Medical Systems International, Inc.; Boston Scientific BV; Boston Scientific Corporation Northwest Technology Center, Inc.; Boston Scientific Cupertino Corp.; Boston Scientific Ireland Limited; Boston Scientific Japan KK; Boston Scientific Limited; Boston Scientific Neuromodulation Corporation; Boston Scientific Scimed, Inc. (formerly known as Schneider (USA), Inc.); Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.); Cardiac Pacemakers, Inc.; Cardiac Pathways Corporation; Cardiothoracic Systems, Inc.; Cardiovascular Innovations Canada, Inc.; Catheter Innovations Corp.; Corvita Canada, Inc.; Corvita Corporation; Corvita Europe S.A.; CryoVascular Systems, Inc.; Embolic Protection, Inc.; Embro Vascular, LLC; Enable Medical Corporation; EndoTex Interventional Systems, Inc.; Endovascular Technologies, Inc. (EVT); Enteric Medical Technologies, Inc.; EP Technologies, Inc.; Fidus Medical Technology Corporation; Guidant Corporation; Guidant Holdings, Inc.; Guidant Intercontinental Corporation; Guidant Investment Corporation; Guidant Puerto Rico Sales Corporation; Guidant Sales Corporation; Heart Technologies; Inflow Dynamics Inc.; Intermedics, Inc.; Interventional Technologies, Inc.; Laboratoires Corvita S.A.R.L.; Meadox Medicals, Inc.; NAMIC Eireann Limited; NAMIC International, Inc.; Nilo Holding, S.A.; Origin Medsystems, Inc.; Precision Vascular Systems, Inc.; Prohold Medical Corporation; Prohold Technologies, Inc.; Provasis Therapeutics, Inc.; Quanum Corporation; Radio Therapeutics Corporation; Rubicon Medical Corporation; Rubicon Medical, Inc.; Schneider (Europe) GmbH; Schneider Belgium NV; Schneider Holland BV; Schneider Ireland BV; Schneider Puerto Rico (formerly known as NAMIC Caribe, Inc.); Schneider/NAMIC; Scimed Life Systems, Inc.; Smart Therapeutics, Inc.; Sub-Q, Inc.; Symbiosis Corporation; Target Therapeutics, Inc.; TriVascular, Inc.; and Vesica;

hereby authorize the following registered patent attorneys/agents (1) to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent entities, (2) to execute power of attorney documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, to appoint and/or establish any attorneys, agents, and/or law firms to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, in any foreign or international patent applications filed with any foreign and/or international patent offices, and (3) to execute assignment and ownership documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent offices:

Victoria Aguilera Poissant Reg. No. 56,871	Albert K. KauReg. No. 40,672	
Alana Bergman Reg. No. 47,420	Philip H. LeeReg. No. 50,645	
James R. Chiapetta Reg. No. 39,634	Kurt W. LockwoodReg. No. 40,704	
Richard R. Clapp Reg. No. 31,751	Jeffrey Z. MannReg. No. 51,994	
Jeffrey P. Cook Reg. No. 48,649	Steven A. McAuleyReg. No. 46,084	
Luke R. Dohmen Reg. No. 36,783	Todd P. MessalReg. No. 42,883	
Peter J. Gafner Reg. No. 36,517	Tyler L. NasiedlakReg. No. 40,099	
Lori J. Heinrichs	William J. ShawReg. No. 43,111	
Lawrence J. Knopf, Senior Vice President and Deputy General Counsel	n/ii/is Date	
Enwience J. Knopi, Samor vice resident and Deputy Scheim Course.	Ditte	
COMMONWEALTH OF MASSACHUSETTS )	•	
COUNTY OF MIDDLESEX		
On this 15th day of December 2008 before ma personally appeared I awronce I Known to me known and known to me to be the person		

On this 15th day of December 2008 before me personally appeared Lawrence J. Knopf to me known and known to me to be the person described in and who executed the foregoing instrument, and he duly acknowledged to me that he executed the same for the uses and purposes set forth herein.

non Eidend

**Notary Public** 

Nona F. Hurd NOTARY PUBLIC My commission expires Sept 18, 2009